Cycrimine

DB00942ApprovedSmall molecule

Cycrimine is a drug used to reduce levels of acetylcholine to return a balance with dopamine in the treatment and management of Parkinson's disease.

Mechanism: Cycrimine binds the muscarinic acetylcholine receptor M1, effectively inhibiting acetylcholine. This decrease in acetylcholine restores the normal dopamine-acetylcholine balance and relieves the symptoms of Parkinson's disease.
Curator reviewed
Primary indication: For treatment and management of Parkinson's disease.Curator reviewed
Formula / weight: C₁₉H₂₉NO · 287.4397 g/mol (avg)

Resolves to

Compound

Clinical / RWD

Structure

InChIKeySWRUZBWLEWHWRI-UHFFFAOYSA-NSMILESOC(CCN1CCCCC1)(C1CCCC1)C1=CC=CC=C1

Targets

What you can answer from here — as of September 13, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

516Drug interactionsStructured to mechanism, not free text

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Cycrimine, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.